SCHEMBL3375787

SCHEMBL3375787

CC(C)(C)OC(=O)c1ccc(CNS(=O)(=O)Cc2ccc(-c3ccc(Oc4ccccc4)cc3)cc2Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
ERCC1 P07992 1/20 0.41
ERCC4 Q92889 1/20 0.41
S1PR1 P21453 1/20 0.41
HDAC1 Q13547 1/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA14 Q9ULX7 2/20 0.39
LIPC P11150 1/20 0.39
LIPG Q9Y5X9 1/20 0.39
CA7 P43166 1/20 0.39
BCL2L1 Q07817 2/20 0.39
MCL1 Q07820 2/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
MAPK14 Q16539 3/20 0.39
SCN9A Q15858 1/20 0.38
AKR1C3 P42330 2/20 0.38
POLB P06746 1/20 0.38
NR1H2 P55055 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14732190 0.79 S1PR1 (0.41) S1PR1SCN9ANR1H2
SCHEMBL3379986 0.74 CA12 (0.41) ALDH1A1CA12CA1CA14CA7
SCHEMBL3380135 0.73 SRD5A2 (0.57) CA1BCL2L1MCL1CA2MAPK14
SCHEMBL3376158 0.73 SCN9A (0.39) ALDH1A1CA12CA1CA14LIPC
SCHEMBL11887260 0.71 PARP10 (0.55) ALDH1A1CA12CA1CA14CA2
SCHEMBL3378390 0.69 FFAR4 (0.43) MAPK14AKR1C3AKR1C2PPARA
SCHEMBL3376011 0.68 SRD5A2 (0.45) ALDH1A1BCL2L1MCL1
SCHEMBL3376848 0.68 KIF11 (0.50) HDAC1CA12CA1CA14LIPC
SCHEMBL3378385 0.67 FABP4 (0.48) PPARA
SCHEMBL6355405 0.66 CA12 (0.63) ALDH1A1CA12CA1CA14CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 ALDH1A1 930/4885ERCC1 4249/4885ERCC4 4617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.